Small-cell lung cancer in the elderly--is age of patient a relevant factor?
Different management procedures for diagnosis and treatment of small-cell lung cancer (SCLC) and other tumours in the elderly have been reported, but there is a lack of data from a communal hospital perspective. Information on clinical parameters such as weight loss, co-morbidity, performance status and investigative procedures for staging of disease and inclusion in clinical trials was recorded for patients in the province of Albacete (Spain). Patients' ages were categorized in two groups: under 70 years and 70 years or more, and a comparison of treatment variables, toxicities, response and time to event measures was carried out. Ninety-five patients were referred to our Unit for treatment. Of these patients, 62% were under 70 years of age and 38% were in the older age category. Clinical variables and staging procedures did not differ between groups. Trial assignment showed a bias in favour of younger patients (11 vs. 1, p = 0.02). No differences in the number of patients without treatment were found, but the older group presented fewer cases of optimal (> or = 4 cycles) therapy, less chemotherapy delivery (smaller mean total doses of cisplatin and etoposide) and smaller mean total dose of radiotherapy (57/45 Gy). The response to treatment (46%/50%) toxicity registered and overall survival did not differ between age categories. Age does not seem to be a relevant prognostic factor in this disease. Carefully calculated dose reductions for chemotherapy in elderly patients based on initial performance status and/or toxicity during treatment may be a useful policy without detrimental implications on outcome.